Hot Stocks To Watch For 2015: Provectus Pharmaceuticals Inc (PVCT)
Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.
PV-10
As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.
PH-10
The Company�� prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.
Over-the-Counter Pharmaceuticals
The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company�� GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users��hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.
The Company�� acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.
Advisors' Opinion:- [By Jake L'Ecuyer]
Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.
- [By Luke Jacobi]
Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.
Top 5 Trucking Stocks To Buy For 2014: Oxygen Biotherapeutics Inc.(OXBT)
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the United States. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It markets its Dermacyte line of products through buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales, independent sales agents, and distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its n ame to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is based in Morrisville, North Carolina.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap Oxygen Biotherapeutics, Inc (NASDAQ: OXBT) surged 87.33% to $2.81 after published results showed that its levosimendan was associated with reduced mortality, meaning its probably time to do a reality check about the stock as well as look at its performance against that of industry benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
Top 5 Trucking Stocks To Buy For 2014: Wilshire Bancorp Inc.(WIBC)
Wilshire Bancorp, Inc. operates as the holding company for Wilshire State Bank that offers a range of financial products and services. It accepts various deposit products that include certificates of deposit, regular savings accounts, money market accounts, checking and negotiable order of withdrawal accounts, installment savings accounts, and individual retirement accounts. The company?s loan portfolio comprises commercial real estate and home mortgage loans, commercial business lending and trade finance, and small business administration lending, as well as consumer loans, including personal loans, auto loans, and other loans. It also provides trade finance services that include issuance and negotiation of letters of credit, handling of documentary collections, advising and negotiation of commercial letters of credit, transfer and issuance of back-to-back letters of credit, and trade finance lines of credit. In addition, the company offers Internet banking services, auto matic teller machines, and armored carrier services. It has 24 full-service branch offices in Southern California, Texas, New Jersey, and the greater New York City metropolitan area; and 6 loan production offices in Colorado, Georgia, Texas, New Jersey, and Virginia. The company was founded in 1980 and is headquartered in Los Angeles, California.
Advisors' Opinion:- [By Rich Smith]
Los Angeles-based Wilshire Bancorp (NASDAQ: WIBC ) is acquiring some Korean banking customers... in New Jersey.
On Monday, Wilshire announced that it has signed a definitive agreement to acquire�New Jersey's BankAsiana, a commercial bank�with three branches serving the Korean-American community in the New York/New Jersey market, boasting total assets of $207.3 million, total net loans of $161.2 million, and total deposits of $164.6 million.
Top 5 Trucking Stocks To Buy For 2014: The Dixie Group Inc.(DXYN)
The Dixie Group, Inc. engages in the manufacture, marketing, and sale of carpets and rugs to residential and commercial customers primarily in the United States. It also offers broadloom and modular carpets for the specified commercial marketplace. The company sells its products under the Fabrica International, Masland Carpets, and the Dixie Home brands. It also processes yarns, and provides carpet dyeing and finishing services to other carpet manufacturers. The company primarily serves interior decorators and designers, selected retailers and furniture stores, luxury home builders, and manufacturers of luxury motor coaches and yachts. The Dixie Group, Inc. was founded in 1920 and is based in Chattanooga, Tennessee.
Advisors' Opinion:- [By Roberto Pedone]
Dixie Group (DXYN) markets, manufactures and sells carpet and rugs to high-end residential and commercial customers through its various sales forces and brands. This stock closed up 10.9% at $11.48 in Thursday's trading session.
Thursday's Volume: 218,000
Three-Month Average Volume: 82,425
Volume % Change: 198%From a technical perspective, DXYN ripped sharply higher here right above some near-term support around $10 with strong upside volume. This stock has been trending sideways inside of a consolidation pattern for the last month, with shares trending between $10 on the downside and $12.05 on the upside. This consolidation pattern is occurring after a strong uptrend for shares of DXYN, which took the stock from $4.99 in March to $10 in August. This spike is now starting to push shares of DXYN within range of triggering a big breakout trade. That trade will hit if DXYN manages to take out Thursday's intraday high at $11.99 and then once it clears its 52-week high at $12.05 with high volume.
Traders should now look for long-biased trades in DXYN as long as it's trending above $11 or Thursday's low of $10.43, and then once it sustains a move or close above those breakout levels with volume that hits near or above 82,425 shares. If that breakout triggers soon, then DXYN will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.
No comments:
Post a Comment